Acquisitions1 April 2026 at 11:08 am
Piramal Pharma Ltd Completes Acquisition of Kenalog® from Bristol-Myers Squibb
AI Summary
Piramal Pharma Ltd has successfully completed the acquisition of Kenalog® and its associated brands from Bristol-Myers Squibb Company. This acquisition was previously announced on 28th January, 2026. Piramal Critical Care B.V., a step-down wholly owned subsidiary of Piramal Pharma Limited, has completed the transaction. The acquisition strengthens Piramal's Complex Hospital Generics portfolio and reinforces its presence across key markets including the United States, Europe, and Asia Pacific.
Key Highlights
- Piramal Pharma Ltd has completed the acquisition of Kenalog® and its associated brands from Bristol-Myers Squibb Company.
- The acquisition was announced on 28th January, 2026 and has now been successfully completed.
- The acquisition strengthens Piramal's Complex Hospital Generics portfolio.
- It reinforces Piramal's presence across key markets including the United States, Europe, and Asia Pacific.
- Piramal Critical Care B.V., a step-down wholly owned subsidiary of Piramal Pharma Limited, has completed the transaction.
PPLPHARMAPharmaceuticals
Piramal Pharma LtdPrice Impact